Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Item 2.02 discloses Vireo's financial results for Q2 2026 (three months ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release reports GAAP revenue of $209.3 million (up 335% YoY), GAAP gross profit of $95.3 million, and adjusted EBITDA of $41.5 million, along with detailed commentary on M&A activity and operational highlights. This is a standard earnings release disclosure material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-11
Item 5.02
ClearSign Technologies appointed Larry M. Saddler to its Board of Directors effective August 6, 2026, to fill a vacant directorship. Saddler is a retired ExxonMobil executive with 40+ years of industry experience in heat transfer and emissions reduction technology. The appointment includes annual cash compensation of $60,000 and stock option grants of $40,000, plus make-whole payments for covered RSUs.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 11, 2026. The Item 2.02 disclosure explicitly states "Terrestrial Energy Inc. announced its financial and operating results for the quarter ended June 30, 2026" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated balance sheets and statements of operations showing a net loss of $9.4 million for Q2 2026, along with detailed financial metrics, cash position ($283.4 million), and operational highlights. This is a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) disclosing financial results including operating expenses, net loss, cash position, and operational highlights. The filing explicitly states "issued a press release that included financial information for its quarter ended June 30, 2026" with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures under Item 2.02. The disclosure includes condensed consolidated balance sheets and statements of operations showing a net loss of $3.2 million for Q2 2026 and cash position of $11.3 million, material information for investors assessing the company's financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
The filing discloses Gain Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release includes condensed consolidated statements of operations and balance sheets, along with detailed discussion of R&D expenses ($2.1M), G&A expenses ($2.5M), net loss per share ($0.11), and cash position ($13.1M). This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
B&G Foods disclosed financial results for Q2 2026 and the first two quarters of 2026, including net sales, net loss/income, diluted EPS, adjusted EBITDA, and segment results, via press release issued on August 11, 2026.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-11
EX-99.1
This is a news release disclosing Franco-Nevada's Q2 2026 financial results, including revenue of $580.9 million (+57% YoY), 132,405 GEOs sold (+18% YoY), operating cash flow of $482.5 million (+12% YoY), and Adjusted EBITDA of $529.7 million (+45% YoY). The document presents quarterly and half-year financial highlights, detailed commodity breakdowns, and portfolio updates. This is a discrete earnings announcement, not a periodic financial report filing, and the results are material to investors assessing the registrant's financial performance and operational trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a straightforward earnings release disclosing Barnwell's financial results for the third fiscal quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states "Barnwell Industries, Inc. issued a press release announcing its financial results for its third fiscal quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly financial metrics including revenue ($3,379,000), net loss ($403,000 consolidated, $440,000 attributable to shareholders), and per-share results ($0.03 loss per share), along with comparative analysis and operational metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This Item 2.02 discloses Anteris Technologies' quarterly financial results for the period ended June 30, 2026, filed as Form 10-Q with the SEC and announced to the ASX. The exhibits include the "Anteris Technologies Announces Results for the Second Quarter of 2026" press release (EX-99.1) and the ASX announcement (EX-99.2) containing condensed consolidated financial statements, revenue figures ($1.5M for six months), and operating losses ($51.7M for six months). This is a standard quarterly earnings release disclosure material to investors assessing the company's financial performance and operational progress.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 94%
filed 2026-08-11
Item 2.05
Comscore announced a substantial workforce reduction and operational restructuring plan (the 'ROI Strategy') authorized by the Board on August 6, 2026, with one-time exit costs of $7–$9 million (primarily severance and termination benefits) and expected annual run-rate savings of $20–$25 million.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-08-11
Item 5.02
The Company disclosed material compensatory arrangements for named executives in connection with the restructuring: CEO Matt McLaughlin's base salary reduced 20% and STIP forfeited for 2026; CFO Mary Margaret Curry's base salary reduced 10%, STIP reduced 50%, plus new equity grants (60,000 options and 60,000 RSUs); and Chief Commercial Officer Steve Bagdasarian's transition agreement with severance modifications.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Broadwind issued a press release on August 11, 2026 announcing Q2 2026 financial results, disclosing revenue of $24.3 million (+67% y/y), a GAAP loss from continuing operations of ($0.7) million, and Adjusted EBITDA of $1.6 million, along with an investor presentation and segment-level results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
Harvard Bioscience issued a press release on August 11, 2026, announcing financial results for Q2 2026 and the six-month period ended June 30, 2026, including revenue of $22.7 million (Q2) and $43.5 million (six months), along with updated full-year 2026 guidance raising revenue growth expectations to 3%-5%. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1, and is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-11
Item 7.01
This Item 7.01 disclosure furnishes a corporate investor presentation that updates the investment community on Harvard Bioscience's business strategy, recent actions, and financial guidance. The presentation covers multiple material operational and strategic developments including new executive leadership (CEO and CFO appointments), debt refinancing with extended maturity and $3M annual cash savings, board expansion, manufacturing consolidation (Project Viking) expected to deliver $3-4M EBITDA improvement, and a strategic refocus on Translational Science products. While these individual items might fit specific categories (exec_appointment, debt_issuance, workforce_reduction), the disclosure as a whole is a comprehensive investor update that does not center on any single event type but rather presents an integrated strategic narrative. The operational and strategic nature of the content, combined with the lack of a single dominant event, makes operational_other the most appropriate classification.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-11
EX-99.1
The press release announces the appointment of J. Michael Rolland to Intermap's Board of Directors. This is a clear executive/governance appointment disclosing a person taking a board role. Rolland brings significant infrastructure financing experience and his appointment is explicitly framed as supporting the company's capital expansion strategy, making it material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-11
EX-99.1
This is a press release disclosing Westport's second quarter 2026 financial results, including consolidated revenues ($2.7M vs. $12.5M prior year), net loss from continuing operations ($11.4M vs. $5.1M), and detailed segment performance. The exhibit explicitly states "Westport Reports Second Quarter 2026 Financial Results" and provides comprehensive financial tables and operational highlights typical of an earnings release. The disclosure is material as it reveals significant revenue decline (78%), increased losses, and critically, a going-concern warning that "cash and cash equivalents will not be sufficient to fund our operations through the next twelve months."
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-11
Tower Semiconductor announced the availability of OpenLight's photonic Process Design Kit (PDK) for Tower's PH18DA InP-on-silicon photonics platform integrated into Cadence's EDA tools. This represents a material strategic partnership and product ecosystem expansion enabling customers to design advanced photonic integrated circuits, advancing Tower's SiPho technology platform and market positioning in high-value analog semiconductors for AI infrastructure and optical interconnects.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-11
EX-99
This is a press release announcing Ceragon's Q2 2026 financial results, dated August 11, 2026. It discloses quarterly revenues ($93.9 million, up 14.2% YoY), GAAP net loss of $2.1 million, and non-GAAP net income of $1.7 million, along with detailed financial statements (condensed consolidated statements of operations, balance sheets, and cash flows) and updated 2026 full-year guidance. The document explicitly states "Ceragon Reports 2026 Second Quarter Financial Results" and includes CEO commentary on business performance and outlook. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-11
The 6-K discloses results of an Annual General Meeting of shareholders held on August 11, 2026, reporting adoption of five resolutions: re-election of four directors, election of a new external director (Amit Foox), extension of exculpation and indemnification letters for Revital Cohen-Tzemach, and re-appointment of the independent auditor Kost Forer Gabbay & Kasierer. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, reporting the outcomes of shareholder votes on governance and audit matters.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure announces financial results including revenues of $235.9 million, net income of $30.9 million, and Adjusted EBITDA of $93.9 million, with the full press release furnished as Exhibit 99.1. The filing includes condensed consolidated financial statements and segment information typical of quarterly earnings disclosures.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-08-11
EX-99.1
Silicon Motion announced the pricing of a $1.0 billion offering of convertible senior notes due 2031, with an upsized offering from the previously announced $800 million. The press release discloses the terms, conversion features, and intended use of proceeds ($980 million net, to be used for general corporate purposes and to repay credit agreement amounts). This is a material debt issuance creating a direct financial obligation.
View raw filing on EDGAR →
6-K
Periodic Interim
confidence 95%
filed 2026-08-11
The 6-K furnishes a board resolution approving ChipMOS's consolidated financial statements for the six-month period ended June 30, 2026, together with detailed interim financial results (revenue, profit, assets, liabilities, and EPS). This is a periodic interim financial report, not a discrete event or earnings press release. The filing discloses the company's half-year financial position and performance as required by Taiwan Stock Exchange rules.
View raw filing on EDGAR →
6-K
Earnings release
confidence 97%
filed 2026-08-11
EX-99.1
ChipMOS Technologies reported second quarter 2026 financial results with revenue of NT$7,383.1 million (up 28.7% year-over-year), gross margin expansion to 18.0%, and net earnings of NT$1.28 per share, marking a return to profitability from a loss in Q2 2025.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
This is a clear earnings release disclosing quarterly financial results for the three and six months ended June 30, 2026. The press release, attached as Exhibit 99.1, presents net sales of $102.9 million, net income of $1.5 million ($0.07 per share), adjusted EBITDA of $9.8 million, and other key operating metrics. Item 2.02 explicitly states the company "issued a press release announcing its results for the three months and six months ended June 30, 2026," which is the hallmark of an earnings_release disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
This is a clear earnings release disclosing Kardigan's financial results for the fiscal quarter ended June 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing second quarter 2026 financial results with detailed operating expenses, net loss ($116.2 million), cash position ($660.7 million), and per-share metrics. The disclosure is material to investors as it provides the company's quarterly financial performance and cash runway guidance through multiple clinical milestones.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-08-11
Item 1.01
Green Thumb Industries' subsidiaries entered into a material amendment agreement with RYTHM, Inc. modifying the terms of $72 million in convertible notes, 9.7 million pre-funded warrants, and a shared services agreement, with the removal of beneficial ownership limitations representing a significant restructuring of the GTI-RYM relationship and materially changing GTI's economic interest and control rights in RYM.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Cardinal Infrastructure Group Inc. issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, including record quarterly revenue of $226.9 million (up 114% year-over-year), adjusted EBITDA of $28.1 million, and updated 2026 full-year guidance to $880–$900 million in revenue.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Upstream Bio disclosed its Q2 2026 financial results and business highlights on August 11, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial statements (balance sheet and statements of operations), operating metrics (R&D and G&A expenses, net loss of $39.7 million), and clinical development updates for its lead program verekitug. This is a standard earnings release for a clinical-stage biotech company, filed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Aura Biosciences issued a press release announcing its financial results for Q2 2026 (quarter ended June 30, 2026), disclosing a net loss of $45.6 million, cash position of $323.8 million, R&D expenses of $30.7 million, and G&A expenses of $17.3 million, along with business highlights and operational updates.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-08-11
Item 2.05
Aura Biosciences announced an organizational realignment involving a workforce reduction of approximately 20%, with estimated restructuring costs of $2.9–$3.2 million primarily for severance benefits and related exit costs, expected to be substantially complete by the end of Q3 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-11
Item 5.02
Aura Biosciences appointed Susan Abu-Absi as Chief Operating Officer effective August 10, 2026, with compensation terms including $520,000 base salary, 45% bonus target, and approximately 400,000 shares in equity awards (60% options, 40% RSUs). The company also appointed Erica Kratz as Chief Regulatory Officer and Julie Person as Chief People Officer.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a clear earnings release disclosing Hemab Therapeutics' financial results for Q2 2026 (quarter ended June 30, 2026), issued on August 11, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results including cash position ($457.5M), R&D expenses ($20.3M), G&A expenses ($5.7M), and net loss ($24.2M or $0.80 per share), along with corporate and pipeline updates. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
CalciMedica issued a press release on August 11, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 cash position ($18.6 million), R&D expenses ($2.1 million), G&A expenses ($1.9 million), and net loss ($7.7 million or $0.45 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Tango Therapeutics issued a press release on August 11, 2026 disclosing its financial results for the quarter ended June 30, 2026, including consolidated statements of operations and balance sheets. The filing explicitly states this is being disclosed pursuant to Item 2.02 (Results of Operations and Financial Condition), and the press release is furnished as Exhibit 99.1. This is a standard quarterly earnings release for a public company, disclosing net loss of $55.3 million for Q2 2026 and cash position of $1.0 billion, along with clinical pipeline updates and corporate milestones.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-11
Item 2.02
This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states that Ambiq "issued a press release to report financial results for its second quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The exhibit contains detailed financial statements (consolidated balance sheets, statements of operations, cash flows), management commentary, and forward guidance for Q3 2026. The results show material growth (90% YoY net sales increase, gross profit more than doubled) and would affect a reasonable investor's assessment of the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 94%
filed 2026-08-11
Item 2.02
Sagimet disclosed Q2 2026 financial results via press release (Exhibit 99.1), reporting a net loss of $13.953 million for the quarter and $24.6 million for the six-month period, with a cash position of $257.6 million, along with corporate updates on clinical trial progress and equity financing.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $5.7 million, net loss of $13.9 million ($0.14 per share), R&D and G&A expenses, and cash position of $155.2 million. The filing includes audited financial statements (Statements of Operations and Balance Sheets) as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 11, 2026 disclosing financial results for the quarter ended June 30, 2026, including collaboration revenue, R&D and G&A expenses, net loss of $6.6 million, and cash position of $43.2 million. The filing includes condensed balance sheets, statements of operations, and cash flow statements for the interim period, along with corporate highlights and forward-looking guidance on clinical trial milestones. This is material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-11
Item 2.02
Neuronetics disclosed Q2 2026 financial results via press release, reporting total revenue of $41.6 million (up 9.1% year-over-year), improved gross margin to 51.1%, reduced net loss to $3.4 million from $10.1 million, and achievement of positive adjusted EBITDA of $0.3 million, along with updated full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a clear earnings release disclosing Kalaris Therapeutics' financial results for the quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states the company "issued a press release announcing the Company's financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated statements of operations and balance sheets, along with detailed discussion of R&D expenses ($9.0M), G&A expenses ($3.4M), net loss ($11.5M), and cash position ($93.5M). This is a material disclosure affecting investor assessment of the registrant's financial condition and operational performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
LB Pharmaceuticals issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed statements of operations and balance sheet data. The disclosure includes quarterly R&D expenses ($44.1M vs. $2.4M prior year), G&A expenses ($9.8M vs. $2.4M), and net loss ($51.6M vs. $4.9M), along with cash position and operational updates. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-11
Item 5.02
ManpowerGroup appointed John B. Gibson, Jr., President and CEO of Paychex, to its Board of Directors effective September 1, 2026. The disclosure centers on the appointment of a director to the board and his committee assignment, with the board size increasing from ten to eleven directors. This is a clear executive appointment event under Item 5.02, material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-11
Item 1.01
Mereo entered into an Option and License Agreement with Sentynl Therapeutics granting Sentynl exclusive U.S. commercial rights to alvelestat while Mereo retains rest-of-world rights and leads global development. The agreement includes $40 million in upfront and R&D payments, up to $435 million in milestone payments, and double-digit royalties on U.S. sales.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-08-11
Item 8.01
The Company entered into a 10b5-1 plan to repurchase up to $25 million of Class A Common Stock, which constitutes a share-repurchase program — a form of return of capital to shareholders. While not a traditional dividend, share repurchases are classified under the dividend_distribution category as they represent a capital return mechanism. The $25 million authorization is material to a reasonable investor assessing capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (three months ended June 30, 2026) filed on August 11, 2026. The disclosure includes financial results (net loss of $44.1 million, R&D expenses of $35.9 million, G&A expenses of $11.7 million), balance sheet data (cash position of $384.3 million), and condensed consolidated statements of operations. The full press release is attached as Exhibit 99.1, which is the typical format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-11
Item 5.02
Barry C. McCarthy, President and CEO of Deluxe Corporation, was appointed as a new director to Radian Group Inc.'s Board of Directors, increasing the Board size from eleven to twelve members. McCarthy brings nearly four decades of leadership experience in payments, financial services, and technology.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-11
EX-99.1
Apollomics announced a $10 million private placement of unregistered Class A ordinary shares comprising 700,001 shares issued under Section 4(a)(2) and Regulation D Rule 506. The transaction includes $8 million in cash subscriptions at $15/share plus $2 million in convertible note conversion at $12/share. This is a classic dilutive equity issuance to raise capital, with participation from insiders (CEO Chen, CFO Lin, COO Chen affiliate), characteristic of a PIPE-like transaction material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Diodes disclosed second quarter 2026 financial results on August 5, 2026, reporting revenue of $445.5 million (up 22% year-over-year), gross profit margin of 33.1%, and GAAP net income of $1.00 per diluted share, along with forward guidance for Q3 2026. The earnings conference call transcript and detailed financial metrics were furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-11
Item 2.02
Immunic reported financial results for Q2 2026 ended June 30, 2026, and provided a corporate update via press release.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-11
Item 5.02
Elena Ridloff was appointed to the Board of Directors effective August 6, 2026, bringing 20+ years of biopharmaceutical leadership experience in finance, capital markets, and corporate development to strengthen the board's expertise as the company approaches pivotal Phase 3 readout. Dr. Daniel Vitt resigned from the board and his employment was terminated pursuant to a separation agreement.
View raw filing on EDGAR →